(Verbatim from the Applicant): Decreased osteoblastogenesis in old age is accompanied by an increase in adipogenesis in the bone marrow of animals and humans. Since osteoblasts and adipocytes share a common mesenchymal progenitor, it is hypothesized that the osteopenia associated with aging is the result of changes in mesenchymal cell commitment and differentiation in the bone marrow. These changes result in an increase in adipogenesis at the expense of osteoblastogenesis. We demonstrated that marrow stroma derived from old animals consists of a larger number of cells that express PPARgamma2, an adipocyte specific transcription factor, than marrow stroma derived from young animals. In addition, we have shown that forced expression of PPARgamma2 in cells of osteoblastic lineage causes their terminal differentiation to adipocytes and simultaneously suppresses the osteoblastic phenotype through an inhibition of expression of osteoblast-specific transcription factor Osf2/Cbfal. Based on the above, we propose the hypothesis that increased expression of PPARgamma2 in mesenchymal progenitors, and/or production of PPARgamma2 ligands, causes increased marrow fat development and decreased osteoblast formation, resulting in the osteopenia that occurs with advancing age. To address aspects of this hypothesis, we propose the following Specific Aims: (1) determine the mechanisms responsible for suppression of PPARgamma2 promoter activity in cells of osteoblast lineage and bone marrow mesenchymal progenitors; (2) determine whether the anti-osteoblastic and/or pro-adipocytic effects of PPARgamma2 are mediated through SMADs; and (3) determine the role of PPARgamma2 on the fate of mesenchymal progenitors of bone marrow and bone formation in vivo. Understanding mechanisms which lead to increased adipogenesis and decreased osteoblastogenesis with aging may create the possibility for direct modulation of the fate of mesenchymal progenitor cells by preventing adipogenic conversion of potential osteoblasts. Such intervention may slow down or even prevent age-related bone loss.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG017482-05
Application #
6897232
Study Section
Orthopedics and Musculoskeletal Study Section (ORTH)
Program Officer
Kohanski, Ronald A
Project Start
2001-06-01
Project End
2007-05-31
Budget Start
2005-06-01
Budget End
2007-05-31
Support Year
5
Fiscal Year
2005
Total Cost
$219,000
Indirect Cost
Name
University of Arkansas for Medical Sciences
Department
Other Health Professions
Type
Schools of Medicine
DUNS #
122452563
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Shockley, Keith R; Lazarenko, Oxana P; Czernik, Piotr J et al. (2009) PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 106:232-46
Schwartz, Ann V; Garnero, Patrick; Hillier, Teresa A et al. (2009) Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 94:2380-6
Lecka-Czernik, B; Ackert-Bicknell, C; Adamo, M L et al. (2007) Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 148:903-11
Lazarenko, Oxana P; Rzonca, Sylwia O; Hogue, William R et al. (2007) Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148:2669-80
Lecka-Czernik, Beata (2006) PPARs and Bone Metabolism. PPAR Res 2006:18089
Lecka-Czernik, Beata; Suva, Larry J (2006) Resolving the Two ""Bony"" Faces of PPAR-gamma. PPAR Res 2006:27489
Ranganathan, Gouri; Unal, Resat; Pokrovskaya, Irina et al. (2006) The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment. J Lipid Res 47:2444-50
Schwartz, Ann V; Sellmeyer, Deborah E; Vittinghoff, Eric et al. (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349-54
Lazarenko, Oxana P; Rzonca, Sylwia O; Suva, Larry J et al. (2006) Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone 38:74-84
Rzonca, S O; Suva, L J; Gaddy, D et al. (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401-6

Showing the most recent 10 out of 12 publications